But with Derm Assist available free, how will the company make money?
Abbott’s latest aortic valve launch is unlikely to gain it a meaningful slice of the market; meanwhile, Edwards’ attention has switched to tricuspid.
A US advisory panel has largely endorsed three anti-PD-(L)1 drugs, with voting apparently driven by the availability of alternatives.
Planning for this week’s three-day adcom on US accelerated approvals for anti-PD-(L)1 drugs? Here’s the background info you need.
The US pauses use of JNJ-78436735 after six cases of cerebral venous sinus thrombosis.
Picking up the Lilly cast-off might not have been an easy win for Provention after all.
The link between Astrazeneca’s vaccine and blood clots strengthens, but forecasts show that it was never expected to generate huge sales.
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.